Xaar PLC
20 December 2000
20 December 2000
Xaar plc
FIRST LICENCE SIGNED IN USA
Xaar plc ('Xaar'), the Cambridge-based inkjet printing technology group, has
today announced that it has signed a special licence agreement with a US
corporation. This is Xaar's first licence agreement in the US.
The agreement covers a limited number of Xaar patents and is focussed on
industrial printing applications.
Although the terms of the licence and the identity of the licensee cannot be
disclosed under the terms of the contract, the licence fee will contribute
towards the results for the year to 31 December 2000.
Xaar now has 11 licensees for its ink jet printing technology including large
corporations in Japan, Europe and the USA.
Jan Fineman, Chief Executive of Xaar said :
'This licence represents an important step for Xaar as it extends the
opportunities for our technology to become more widely used in the
important US market. It marks a very encouraging conclusion to a year of
significant progress for Xaar.'
Ends
Jan Fineman, Chief Executive or Jonathan Lowe, Finance Director at Xaar on
Tel: 01223-423663
Steve Liebmann or Lisa Baderoon at Buchanan Communications on
Tel: 020 7-466-5000
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.